相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparative analysis of botulinum toxin injection after corrective rhinoplasty for deviated nose and alar asymmetry
Won Lee et al.
JOURNAL OF COSMETIC DERMATOLOGY (2021)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients
Berthold-Josef Rzany et al.
AESTHETIC SURGERY JOURNAL (2020)
Updates on Botulinum Neurotoxins in Dermatology
Edith Hanna et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2020)
The Novel Clostridial Neurotoxin Produced by Strain IBCA10-7060 Is Immunologically Equivalent to BoNT/HA
Yongfeng Fan et al.
TOXINS (2020)
Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review
Rami Burstein et al.
HEADACHE (2020)
Efficacy and Safety of Letibotulinum Toxin A for the Treatment of Essential Blepharospasm
Ji Hyun Kim et al.
JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY (2020)
A multicenter, randomized, open-label comparative study of prabotulinumtoxinA with two different dosages and diverse proportional injection styles for the reduction of gastrocnemius muscle hypertrophy in Asian women
Youngchul Suh et al.
DERMATOLOGIC THERAPY (2019)
Identification of a Botulinum Neurotoxin-like Toxin in a Commensal Strain of Enterococcus faecium
Sicai Zhang et al.
CELL HOST & MICROBE (2018)
Identification of a novel botulinum neurotoxin gene cluster in Enterococcus
Jason Brunt et al.
FEBS LETTERS (2018)
Safety and efficacy of DaxibotulinumtoxinA for injection (RT002) in cervical dystonia (CD): Results of a phase 2, dose escalating study
D. Truong et al.
PARKINSONISM & RELATED DISORDERS (2018)
The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A Subtypes
Sabine Pellett et al.
MBIO (2018)
Engineering of Botulinum Neurotoxins for Biomedical Applications
Robert P. Webb
TOXINS (2018)
Safety and Efficacy of EB-001, a Novel Type E Botulinum Toxin, in Subjects with Glabellar Frown Lines: Results of a Phase 2, Randomized, Placebo-Controlled, Ascending-Dose Study
Steve G. Yoelin et al.
PLASTIC AND RECONSTRUCTIVE SURGERY (2018)
AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients
Malgorzata Field et al.
TOXINS (2018)
Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose-Escalation Multicenter Study
Joseph Jankovic et al.
MOVEMENT DISORDERS CLINICAL PRACTICE (2018)
A phase 2, open-label, dose-escalating study to evaluate the safety and preliminary efficacy of daxibotulinumtoxina for injection (RT002) in isolated cervical dystonia
Cynthia L. Comella et al.
TOXICON (2017)
Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors
Liang Tao et al.
NATURE COMMUNICATIONS (2017)
Efficacy and Safety of Letibotulinum Toxin A for the Treatment of Dynamic Equinus Foot Deformity in Children with Cerebral Palsy: A Randomized Controlled Trial
Hyun Jung Chang et al.
TOXINS (2017)
Historical Perspectives and Guidelines for Botulinum Neurotoxin Subtype Nomenclature
Michael W. Peck et al.
TOXINS (2017)
Engineering Botulinum Neurotoxin C1 as a Molecular Vehicle for Intra-Neuronal Drug Delivery
Edwin J. Vazquez-Cintron et al.
SCIENTIFIC REPORTS (2017)
Safety and efficacy of letibotulinumtoxinA(BOTULAX®) in treatment of post stroke upper limb spasticity: a randomized, double blind, multi-center, phase III clinical trial
Kyung Hee Do et al.
CLINICAL REHABILITATION (2017)
N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A
Guorui Yao et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2016)
The Botulinum Toxin as a Therapeutic Agent: Molecular Structure and Mechanism of Action in Motor and Sensory Systems
Raj Kumar et al.
SEMINARS IN NEUROLOGY (2016)
N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A
Guorui Yao et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2016)
Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice
Francesco Scaglione
TOXINS (2016)
The first non Clostridial botulinum-like toxin cleaves VAMP within the juxtamembrane domain
Irene Zornetta et al.
SCIENTIFIC REPORTS (2016)
Safety and Efficacy of RT002, an Injectable Botulinum Toxin Type A, for Treating Glabellar Lines: Results of a Phase 1/2, Open-Label, Sequential Dose-Escalation Study
Enrique Garcia-Murray et al.
DERMATOLOGIC SURGERY (2015)
Botulinum neurotoxin homologs in non-Clostridium species
Michael J. Mansfield et al.
FEBS LETTERS (2015)
Molecular Characterization of a Novel Botulinum Neurotoxin Type H Gene
Nir Dover et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
A Novel Strain of Clostridium botulinum That Produces Type B and Type H Botulinum Toxins
Jason R. Barash et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Botulinum toxin type A products are not interchangeable: a review of the evidence
Mitchell F. Brin et al.
BIOLOGICS-TARGETS & THERAPY (2014)
Engineering Clostridia Neurotoxins with elevated catalytic activity
Jiubiao Guo et al.
TOXICON (2013)
Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B
Jiafu Wang et al.
BIOCHEMICAL JOURNAL (2012)
Five-year experience with incobotulinumtoxinA (Xeomin®): the first botulinum toxin drug free of complexing proteins
D. Dressler
EUROPEAN JOURNAL OF NEUROLOGY (2012)
Botulinum toxin for myofascial pain syndromes in adults
Adriana Soares et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2012)
Syntaxin Requirement for Ca2+-Triggered Exocytosis in Neurons and Endocrine Cells Demonstrated with an Engineered Neurotoxin
Dongsheng Wang et al.
BIOCHEMISTRY (2011)
Xeomin®: an innovative new botulinum toxin type A
J. Frevert
EUROPEAN JOURNAL OF NEUROLOGY (2009)
Cell entry strategy of clostridial neurotoxins
Thomas Binz et al.
JOURNAL OF NEUROCHEMISTRY (2009)
Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics
Jiafu Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
The use of botulinum neurotoxin type A (BoNTA) in urology
A. Apostolidis et al.
JOURNAL OF NEURAL TRANSMISSION (2008)
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay
Mitchell F. Brin et al.
MOVEMENT DISORDERS (2008)
From poison to remedy: the chequered history of botulinum toxin
F. J. Erbguth
JOURNAL OF NEURAL TRANSMISSION (2008)
The structure and mode of action of different botulinum toxins
J. O. Dolly et al.
EUROPEAN JOURNAL OF NEUROLOGY (2006)
A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4
Joseph W. Arndt et al.
JOURNAL OF MOLECULAR BIOLOGY (2006)
Different types of botulinum toxin in humans
R Eleopra et al.
MOVEMENT DISORDERS (2004)
Historical notes on botulism, Clostridium batulinum, botulinum toxin, and the idea of the therapeutic use of the toxin
FJ Erbguth
MOVEMENT DISORDERS (2004)
Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction
MF Lew
CLINICAL JOURNAL OF PAIN (2002)
Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions
KR Aoki et al.
EUROPEAN JOURNAL OF NEUROLOGY (2001)
分享论文
